AstraZeneca COPD drug tozorakimab shows benefits across patient groups
AstraZeneca said tozorakimab for chronic obstructive pulmonary disease showed benefits across a broad patient population in late-stage clinical trials, supporting its expectation of multibillion-dollar sales.